- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00827099
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving umbilical cord blood transplant together with fludarabine, melphalan, and antithymocyte globulin works in treating patients with hematologic cancer.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To evaluate the 100-day transplant-related (non-relapse) mortality in patients with hematologic malignancies undergoing reduced-intensity conditioning comprising fludarabine phosphate, melphalan, and anti-thymocyte globulin followed by sequential umbilical cord blood transplantation (UCBT) from 2 partially-matched unrelated donors.
Secondary
- To evaluate the 12-month transplant-related (non-relapse) mortality.
- To evaluate the days to neutrophil engraftment (ANC > 500/mm³).
- To evaluate the days to platelet engraftment (platelet count > 20,000/mm³ [unsupported]).
- To evaluate the risk of acute and chronic graft-vs-host disease.
- To evaluate percent donor chimerism contribution of each cord unit.
- To evaluate relapse rate.
- To evaluate disease-free and overall survival.
- To evaluate transfusion support needed for UCBT recipients.
OUTLINE:
- Conditioning regimen: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, melphalan IV over 30-60 minutes on day -2, and anti-thymocyte globulin IV over 4-6 hours on days -4 to -2.
- Transplantation: Patients undergo two sequential umbilical cord blood transplantations on day 0.
- Graft-vs-host disease (GVHD) prophylaxis: Patients receive tacrolimus IV continuously and then orally twice daily beginning on day -1 and continuing until day 60, followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or orally twice daily beginning on day 0 and continuing until day 30, followed by a taper until day 60 in the absence of GVHD.
After completion of study treatment, patients are followed periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Blood and Marrow Transplant Group of Georgia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of hematologic malignancy for which a reduced-intensity allogeneic stem cell transplantation is deemed clinically appropriate, including any of the following:
Chronic myelogenous leukemia, meeting one of the following criteria:
- In first chronic phase AND failed imatinib mesylate therapy, defined as failure to obtain a hematologic remission by 3 months or major cytogenetic response (Ph+ cells < 35%) by 12 months, or demonstrated clonal evolution or disease progression while on therapy
- In accelerated phase with < 15% blasts
- In blast crisis that has entered into a second chronic phase following induction chemotherapy
Acute myelogenous leukemia, meeting one of the following criteria:
- In second or subsequent completion remission*
- Failed primary induction chemotherapy, but subsequently entered into a complete remission* with ≤ 2 subsequent re-induction chemotherapy treatment(s)
- In first complete remission* with poor-risk cytogenetics NOTE: *Complete remission is defined as < 5% blasts in bone marrow, no definitive evidence of disease by morphology, flow cytometry, or genetic studies, and no circulating blasts. Neutrophil and platelet count recovery will not be required.
Acute lymphoblastic leukemia, meeting one of the following criteria:
- In second or subsequent complete remission
- In first complete remission AND t(9;22)
Myelodysplastic syndromes, meeting the following criteria:
- High-risk disease, defined as International Prognostic Scoring System score of ≥ 1.5
- Less than 10% blasts at the time of study enrollment
Chronic myelomonocytic leukemia
- Less than 10% blasts at the time of study enrollment
Myeloid metaplasia with myelofibrosis with poor-risk features, meeting one of the following criteria:
- Age < 55 years AND a Lille score of 1
- Lille score of 2
- Hemoglobin < 10 g/dL AND abnormal karyotype
Chronic lymphocytic leukemia/prolymphocytic leukemia, meeting all of the following criteria:
- Rai stage I-IV disease
- Failed ≥ 1 prior chemotherapy regimen, including fludarabine, or autologous stem cell transplantation
- Chemosensitive or stable, non-bulky disease prior to transplant
- Received ≤ 3 prior chemotherapy regimens (monoclonal antibody therapy and involved-field radiotherapy are not considered prior regimens)
Low-grade B-cell non-Hodgkin lymphoma (NHL) (small lymphocytic lymphoma, follicular center [grade 1 or 2] lymphoma, or marginal zone lymphoma), meeting all of the following criteria:
- Failed ≥ 1 prior chemotherapy regimen or autologous stem cell transplantation
- Chemosensitive or stable, non-bulky disease prior to transplant
- Received ≤ 3 prior chemotherapy regimens (monoclonal antibody therapy and involved-field radiotherapy are not considered prior regimens)
Intermediate-grade B-cell or T-cell NHL or mantle cell NHL, meeting all of the following criteria:
- Failed to achieve remission or recurred after either conventional chemotherapy or autologous stem cell transplantation
- Chemosensitive, non-bulky disease prior to transplant
Hodgkin lymphoma, meeting all of the following criteria:
- Relapsed after prior autologous stem cell transplantation or after ≥ 2 combination chemotherapy regimens AND ineligible for autologous peripheral blood stem cell transplantation
- Chemosensitive, non-bulky disease prior to transplant
Multiple myeloma, meeting one of the following criteria:
- Relapsed after autologous stem cell transplantation
- Relapsed after conventional therapies AND not a candidate for autologous stem cell transplantation
- No HLA-matched related or unrelated donor available
Has two umbilical cord blood units available that are matched at ≥ 4/6 HLA A, B, and DRB1 with the patient and with each other (HLA C and DQ will not be used in the match strategy)
- Total combined nucleated cell dose from the 2 umbilical cord blood units must be > 3.7 x 10^7 nucleated cells/kg (pre-freeze dose) NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
- Karnofsky performance status 80-100%
- Adapted, weighted Charlson Comorbidity Index < 3
- Serum creatinine ≤ 2.0 mg/dL
- AST or ALT < 3 times upper limit of normal (ULN)
- Bilirubin < 1.5 times ULN
- Not pregnant or nursing
- LVEF ≥ 40%
- DLCO > 50%
- No hypoxia at rest with oxygen saturation < 92% on room air (corrected with bronchodilator therapy)
- No active opportunistic infection (e.g., fungal pneumonia, tuberculosis, or viral infection)
- No active hepatitis B or C infection that, in the opinion of a gastroenterologist or the transplant committee, places the patient at moderate- to high-risk for developing severe hepatic disease
- No HIV infection
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With 100 Day Transplant-related Mortality (TRM)
Time Frame: 100 days
|
100 Day TRM is death within 100 days from transplant related complications
|
100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients That Engrafted Blood Counts by 30 Days After Transplant
Time Frame: Day 30
|
Number of patients whose Absolute Neutrophil Count (ANC) recovered to >500 x10^3/uL for at least 3 consecutive days after transplant
|
Day 30
|
Percentage of Donor and Host Chimerism of Each Cord Blood Unit
Time Frame: day 30, day 60, day 90
|
Evaluate the percentages of donor and host chimerism at multiple times post-transplant including Day 30, Day 60, Day 90 and monthly thereafter if the patient is not considered to have full chimerism.
|
day 30, day 60, day 90
|
Number of Patients Who Experience Acute and Chronic Graft-vs-host Disease After Transplant.
Time Frame: Day 30
|
Patients will be evaluated regularly for the development of graft versus host disease both acute & chronic.
|
Day 30
|
Number of Patients Who Experience Disease Relapse Post-transplant
Time Frame: Day 100, 6 months, 1 year, 18 months, 24 months
|
Patients will have routine restaging to assess disease response at Day 100, 6 months, 1 year, 18 months and 24 months.
If disease relapse is suspected, the patient will be evaluated at that time.
|
Day 100, 6 months, 1 year, 18 months, 24 months
|
Number of Patients Who Survive Following Treatment on This Protocol
Time Frame: Through Death
|
Patients will be followed until death
|
Through Death
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Scott R. Solomon, MD, Blood and Marrow Transplant Group of Georgia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- stage I chronic lymphocytic leukemia
- recurrent grade 3 follicular lymphoma
- recurrent adult diffuse large cell lymphoma
- chronic myelomonocytic leukemia
- de novo myelodysplastic syndromes
- previously treated myelodysplastic syndromes
- secondary myelodysplastic syndromes
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- secondary acute myeloid leukemia
- chronic phase chronic myelogenous leukemia
- recurrent adult Hodgkin lymphoma
- recurrent adult diffuse small cleaved cell lymphoma
- recurrent adult diffuse mixed cell lymphoma
- blastic phase chronic myelogenous leukemia
- relapsing chronic myelogenous leukemia
- Waldenstrom macroglobulinemia
- stage II multiple myeloma
- stage III multiple myeloma
- recurrent grade 1 follicular lymphoma
- recurrent grade 2 follicular lymphoma
- recurrent marginal zone lymphoma
- recurrent small lymphocytic lymphoma
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- nodal marginal zone B-cell lymphoma
- splenic marginal zone lymphoma
- stage I multiple myeloma
- recurrent mantle cell lymphoma
- refractory chronic lymphocytic leukemia
- stage II chronic lymphocytic leukemia
- stage III chronic lymphocytic leukemia
- stage IV chronic lymphocytic leukemia
- recurrent cutaneous T-cell non-Hodgkin lymphoma
- recurrent adult T-cell leukemia/lymphoma
- angioimmunoblastic T-cell lymphoma
- anaplastic large cell lymphoma
- recurrent mycosis fungoides/Sezary syndrome
- adult grade III lymphomatoid granulomatosis
- adult nasal type extranodal NK/T-cell lymphoma
- recurrent adult grade III lymphomatoid granulomatosis
- cutaneous B-cell non-Hodgkin lymphoma
- refractory multiple myeloma
- prolymphocytic leukemia
- chronic idiopathic myelofibrosis
- accelerated phase cml
- adult ALL in remission
- adult AML in remission
- adult AML with 11q23 (MLL) abnormalities
- adult AML with inv(16)(p13;q22)
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Precancerous Conditions
- Lymphoma
- Syndrome
- Myelodysplastic Syndromes
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Leukemia
- Preleukemia
- Plasmacytoma
- Myeloproliferative Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Melphalan
- Fludarabine
- Fludarabine phosphate
- Tacrolimus
- Mycophenolic Acid
- Antilymphocyte Serum
Other Study ID Numbers
- CDR0000632453
- BMTGG-NSH-801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
Clinical Trials on anti-thymocyte globulin
-
Wright State UniversitySanofi; University of Nebraska; University of Arizona; The Methodist Hospital Research... and other collaboratorsCompletedSafety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation (STAT)End-Stage Renal Disease | Kidney FailureUnited States
-
University of CincinnatiGenzyme, a Sanofi CompanyCompletedRenal Transplant Rejection | Transplants and ImplantsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Genzyme, a Sanofi CompanyCompletedMyelodysplastic SyndromesUnited States, Canada
-
M.D. Anderson Cancer CenterCompletedChronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
Genzyme, a Sanofi CompanyTerminatedMyelodysplastic Syndrome (MDS)Germany, United Kingdom, France, Netherlands
-
Hospital de Clinicas de Porto AlegreCompletedImmunosuppression | Kidney Transplant; ComplicationsBrazil
-
European Institute of OncologyIstituto Clinico HumanitasTerminated
-
Swedish Medical CenterGenzyme, a Sanofi CompanyCompletedImmunosuppression | Renal TransplantationUnited States
-
University of California, Los AngelesGenzyme, a Sanofi CompanyWithdrawnHeart Transplantation | Ischemia Reperfusion InjuryUnited States